
IASLC - Neoadjuvant
In this Virtual Tumor Board episode of Lung Cancer Considered, host Dr. Stephen Liu and his guests discuss the dynamic topic of managing resectable stage III NSCLC. Joining him are: Dr. Isabelle S...
7 Mars 202345min

IASLC EGFR AM And PM
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on a specific subset of lung cancer: EGFR exon 20 insertion NSCLC. Joining the podcast are distinguished panel of cl...
23 Feb 202339min

IASLC RET NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion about NSCLC with RET rearrangements, including diagnosis, treatment, and new exciting research coming down the pi...
22 Feb 202334min

IASLC - KRAS G12C
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a conversation on KRAS G12C mutation. Joining the podcast are Dr. Melissa Johnson, the Program Director of Lung Cancer Research at...
21 Feb 202333min

IASLC - LALCA Highlights
The Latin American Conference on Lung Cancer, held in Uruguay, wrapped up in late January. To provide a summary of key findings from the meeting, Lung Cancer Considered host Dr. Narjust Florez interv...
7 Feb 202336min

IASLC FDA Approval Adjuvant Pembrolizumab For NSCLC
On January 26, 2023, the US FDA granted approval of pembrolizumab, an anti-PD-1 antibody, as an adjuvant therapy for patients with resected NSCLC. In this episode of Lung Cancer Considered host Dr. S...
2 Feb 202330min

IASLC IPASS Study 2
In this special episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez discuss the seminal IPASS trial with its principal investigator, Dr. Tony Mok. IPASS was a randomized ph...
25 Jan 202340min

Lung Cancer In Brazil with Clarissa Maria Cerqueira, Mathias Ticiana Leal And Carlos G. Ferreira
In a special episode of Lung Cancer Considered focusing on lung cancer in Brazil, host Dr. Clarissa Mathias, medical oncologist at Oncoclinicas Bahia and Hospital Santa Izabel, is joined by Dr. Tician...
24 Jan 202329min


















